| | If you're having trouble viewing this email, click here | | | | Joining Your Lung Cancer Community | In May I had the amazing opportunity to hang out with 150 lung cancer survivors in Washington DC as part of the HOPE Summit. Last week I again had the chance to spend precious moments with the many lung cancer survivors who attended the IASCL's World Conference on Lung Cancer in Denver. These connections between patients, physicians, and researchers, are unlike anything I would even have conceived of a decade -- or 5 years ago. I will be sharing more in the near future to help all of you find your way -- whatever that happens to be - to feel the support of the amazing lung cancer community we have worldwide. This week I'm excited to share that, not only are lung cancer support groups becoming more available, but groups for people coping with particular genomic types of lung cancer - for example, people with ROS1 mutations and ALK positive lung cancer - have been born. Best wishes until next week, Dr. Lynne | | Lynne Eldridge MD Lung Cancer Expert | | | ALK Positive Lung Cancer - Definition and Treatment | If you are one of the 3 to 10% of people with lung cancer defined as "ALK positive" you are likely learning that one of the new breakthroughs in lung cancer is being able to treat some people as if they had a chronic disease like diabetes -- control the cancer first with one medication designed for people with this mutation, and if and when the tumor becomes resistant, using a second line medication in this category. For people with ROS1 mutations, the medication crizotinib is also making a big difference. It was exciting seeing a group of people with ALK mutations and another with ROS1 mutations having come together this spring in DC, and continuing to keep in touch. For those who are interested, check out this opportunity to participate in the GRACE EGFR, ALK, ROS1 patient forum in San Francisco in October. | | | | Genetic Testing (Molecular Profiling) for Lung Cancer | If you are living with lung cancer and haven't heard about EGFR, ALK, and ROS1, make sure to check out this article. Especially if you are a young adult lung cancer patient - the majority of whom have a targetable gene mutation, i.e. a mutation detected in the lung tumor for which specific treatment is available. Even though these treatments are extending lives and improving quality of life, not everyone who should be tested has been tested. Read more | | | | | | | You are receiving this newsletter because you subscribed to the Lung Cancer newsletter. If you wish to unsubscribe, please click here | | 1500 Broadway, 6th Floor, New York, NY, 10036 | | | | | | | | |
No comments:
Post a Comment